HK1209438A1 - Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma - Google Patents

Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma Download PDF

Info

Publication number
HK1209438A1
HK1209438A1 HK15110269.6A HK15110269A HK1209438A1 HK 1209438 A1 HK1209438 A1 HK 1209438A1 HK 15110269 A HK15110269 A HK 15110269A HK 1209438 A1 HK1209438 A1 HK 1209438A1
Authority
HK
Hong Kong
Prior art keywords
cancer
peptide
cells
cell
plectin
Prior art date
Application number
HK15110269.6A
Other languages
English (en)
Chinese (zh)
Inventor
Kimberley Kelly
Ralph Weissleder
Nabeel Bardeesy
Original Assignee
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation filed Critical The General Hospital Corporation
Publication of HK1209438A1 publication Critical patent/HK1209438A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
HK15110269.6A 2008-04-14 2015-10-19 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma HK1209438A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4481808P 2008-04-14 2008-04-14
US20080044818 2008-04-14

Publications (1)

Publication Number Publication Date
HK1209438A1 true HK1209438A1 (en) 2016-04-01

Family

ID=41199683

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110269.6A HK1209438A1 (en) 2008-04-14 2015-10-19 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma

Country Status (6)

Country Link
US (4) US8829159B2 (enExample)
EP (2) EP2265630B1 (enExample)
JP (3) JP5497006B2 (enExample)
CA (1) CA2758415C (enExample)
HK (1) HK1209438A1 (enExample)
WO (1) WO2009129220A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5497006B2 (ja) * 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
JP2013510094A (ja) * 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
DE102010039289A1 (de) * 2010-08-12 2012-02-16 Leica Microsystems (Schweiz) Ag Mikroskopsystem
WO2013071239A1 (en) * 2011-11-10 2013-05-16 Exosome Diagnostics, Inc. Cerebrospinal fluid assay
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
US10860526B2 (en) * 2012-12-01 2020-12-08 The Regents Of The University Of California System and method of managing large data files
US9606123B2 (en) 2013-03-29 2017-03-28 University Of Virginia Patent Foundation Compositions and methods for diagnosing and monitoring ovarian cancer progression and treatment
US20160166715A1 (en) * 2013-07-30 2016-06-16 Tarveda Therapeutics, Inc. Nanoparticle Diagnostic and Methods for Treating Disease
WO2015054243A1 (en) * 2013-10-07 2015-04-16 Van Dam, Jacques Integrated ultrasound, oct, pa and/or florescence imaging endoscope for diagnosing cancers in gastrointestinal, respiratory, and urogenital tracts
US10668125B2 (en) 2015-11-19 2020-06-02 Niigata University Peptide having highly-shifted accumulation to pancreatic cancer cells and tissues, and use of said peptide
US10611796B2 (en) 2016-03-16 2020-04-07 Council Of Scientific & Industrial Research Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines
JP7197078B2 (ja) * 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
CA3021140A1 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
CN109963875A (zh) * 2016-10-26 2019-07-02 西尔欧集团 靶向并通过辐射能分解癌症的癌症结合不透射线肽类
WO2018227112A1 (en) 2017-06-09 2018-12-13 The Trustees Of Columbia University In The City Of New York Short tat oligomers for drug delivery
CN112105380A (zh) * 2017-10-11 2020-12-18 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体和其用途
MX2020004530A (es) * 2017-11-18 2020-09-18 Magalhaes Nzola De Producto y proceso para emplear conjugados de union a antigeno basados en gc7 (n1-guanil-1,7-diaminoheptano) en terapia de cancer.
US11890352B2 (en) 2018-02-27 2024-02-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
US11358984B2 (en) 2018-08-27 2022-06-14 Regeneran Pharmaceuticals, Inc. Use of Raman spectroscopy in downstream purification
EP3895733A4 (en) * 2018-12-14 2022-03-02 Konica Minolta, Inc. METHOD OF PREDICTING THE ARRIVAL OF A DRUG WITHIN DISEASED TISSUE
CN114814200B (zh) * 2022-05-09 2025-06-27 浙江大学 一种纳米颗粒-荧光标记融合蛋白复合体及其单链dna检测方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3307869A1 (de) 1983-03-05 1984-09-06 Dragoco Gerberding & Co Gmbh, 3450 Holzminden Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe
WO1985003508A1 (en) 1984-02-08 1985-08-15 Cetus Corporation Toxin conjugates
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
JP2594123B2 (ja) 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5169862A (en) 1989-07-07 1992-12-08 Peptide Technologies Corporation Analogs of viscosin and their uses
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
FI954559A7 (fi) 1993-03-29 1995-09-26 Univ Cincinnati YY-peptidin analogit ja niiden käytöt
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5539085A (en) 1993-08-20 1996-07-23 Onyx Pharmaceuticals, Inc. Bcl-2 and R-ras complex
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
ATE264694T1 (de) 1995-01-30 2004-05-15 Daiichi Pure Chemicals Co Ltd Diagnostisches markierungsmittel
US20030100051A1 (en) * 1998-05-12 2003-05-29 Ruben Steven M. 97 human secreted proteins
DE19717904A1 (de) 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6592847B1 (en) 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US20030103975A1 (en) * 1999-11-03 2003-06-05 Jones Jonathan C.R. Modulation of angiogenesis and endothelialization
US20030069180A1 (en) * 2000-06-09 2003-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020177207A1 (en) * 2001-03-14 2002-11-28 Myriad Genetics, Incorporated Tsg101-interacting proteins and use thereof
AUPR290801A0 (en) * 2001-02-06 2001-03-01 Peter Maccallum Cancer Institute, The Substrate binding domain
AU2002320058A1 (en) * 2001-06-06 2002-12-16 The General Hspital Corporation Magnetic-nanoparticle conjugates and methods of use
WO2003030725A2 (en) * 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20050249668A1 (en) * 2002-03-29 2005-11-10 Ralph Weissleder Nir-fluorescent cyanine dyes, their synthesis and biological use
US20040018622A1 (en) * 2002-07-17 2004-01-29 Mitchell Lloyd G. Spliceosome mediated RNA trans-splicing for correction of skin disorders
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US20050095611A1 (en) * 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
US8815235B2 (en) * 2004-06-02 2014-08-26 Jan E. Schnitzer Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
ES2360519T3 (es) * 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
EP2005187A4 (en) * 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
JP5497006B2 (ja) * 2008-04-14 2014-05-21 ザ ジェネラル ホスピタル コーポレイション 膵管腺癌の検出および治療のためのプレクチン−１標的化剤
WO2010068864A2 (en) * 2008-12-12 2010-06-17 University Of Massachusetts Polyesters with grafted zwitterions

Also Published As

Publication number Publication date
US9387265B2 (en) 2016-07-12
EP2265630A4 (en) 2012-12-12
WO2009129220A2 (en) 2009-10-22
JP2014132021A (ja) 2014-07-17
US20150151010A1 (en) 2015-06-04
WO2009129220A3 (en) 2010-01-21
EP2265630A2 (en) 2010-12-29
JP5497006B2 (ja) 2014-05-21
US20190209715A1 (en) 2019-07-11
CA2758415A1 (en) 2009-10-22
US10124077B2 (en) 2018-11-13
JP2011521897A (ja) 2011-07-28
EP2265630B1 (en) 2014-10-29
US20110182814A1 (en) 2011-07-28
US8829159B2 (en) 2014-09-09
EP2862871A1 (en) 2015-04-22
JP6046070B2 (ja) 2016-12-14
JP2017048239A (ja) 2017-03-09
US20170087257A1 (en) 2017-03-30
CA2758415C (en) 2019-06-04

Similar Documents

Publication Publication Date Title
US10124077B2 (en) Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
Sugahara et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors
US12458618B2 (en) Compounds and methods for the detection of TRPV-6 cancers and drug delivery
JP5875518B2 (ja) 膀胱がん特異的なリガンドペプチド
Pung et al. Generation of peptides using phage display technology for cancer diagnosis and molecular imaging
WO2012135824A2 (en) Method of screening for colon cancer using biomarkers
US9581598B2 (en) Diagnosis and treatment of brain tumor
Ruoslahti Targeting Breast Cancer Vasculature
Broome Targeting Cancer Protein Profiles with Split-Enzyme Reporter Fragments to Achieve Chemical Resolution for Molecular Imaging
HK1169661A (en) Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
HK1169661B (en) Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery